More than $35 billion! 278 pharmaceutical companies invested in research and development exposure

recent period, listed companies have issued interim results reports, according to incomplete statistics, 278 A-share and Hong Kong-listed pharmaceutical companies disclosed the 2020 H1 research and development investment, a total amount of more than 35 billion yuan. 120 pharmaceutical companies invested more than 50 million yuan in research and development, of which 5 pharmaceutical companies more than 1 billion (compared with 4 in the same period last year);

68 pharmaceutical companies invested more than 100 million in research and development, Hengrui, Fosun... 5 more than 1 billion 120 pharmaceutical companies invested more than 50 million yuan in research and development in the first half of the year, a total amount of more than 30 billion yuan, of which 68 pharmaceutical companies invested more than 100 million yuan in research and development (compared with 52 in the same period last year), Baiji Shenzhou, China Biopharmaceuticals, Hengrui Pharmaceuticals, Fosun Pharma, Shi Pharmaceutical Group ranked top 5, research and development investment of more than 1 billion yuan, and research and development investment accounted for more than 10% of revenue.Baiji Shenzhou 590 million U.S. dollars (about 4 billion yuan), an increase of 44.99 percent over the same period last year, accounting for 501.27 percent of operating income. By the end of the reporting period, there were more than 1,350 clinical development teams worldwide, conducting or planning 70 clinical trials. Among the new class 1 drugs developed independently, reilly pearl single anti-injection (PD-1), Zebtini capsule (BTK inhibitor) have been approved for market, Parmipali capsule (PARP1 and PARP2 inhibitors) has been declared on the market, BGB-283 capsule (RAF inhibitor) completed Phase I clinical, BGB-3245-MBP capsule, BGB-A333 injections and other clinical batches.Hengrui Pharmaceutical invested 1,863 million yuan in research and development, an increase of 25.56 percent over the same period last year, accounting for 16.49 percent of operating income. During the reporting period, the company obtained 3 batch of innovative drug production, 1 batch of generic drug production and 37 clinical approval of innovative drug; At present, the company has more than 3400 people's research and development team, innovative drugs Arexib, Apatini, thiopental non-gesting, pyrigotin, carelli pearl monoanti, toluene sulphate rhemathion has been approved for listing, the future basic formation of each year there are applications for innovative drugs clinical, every 1-2 years there is a benign development trend of innovative drugs on the market.Fosun Pharma invested 1,689 million yuan in research and development, an increase of 25.02 percent over the same period last year, accounting for 12.06 percent of operating income. During the reporting period, the company introduced the innovative drug AvalancoPa tablets were approved for listing, FKC876 (CAR-T products) declared on the market, 12 generic drugs were approved by the FDA for listing. By the end of the reporting period, the company had nearly 2,300 research and development personnel, and had 248 projects in the research and evaluation of innovative drugs, generic drugs, biosimilars and consistency evaluation, including 17 small molecule innovative drugs, 2 modified new drugs, 21 bio-innovative drugs, 21 biosimilars, and 11 generic drugs. 7 projects, 46 consistent evaluation projects, 2 Chinese medicine; 6 projects are in the process of declaring clinical trials, 33 projects are in clinical trials, 34 projects awaiting approval and listing, 23 products through consistent evaluation; and a total of 22 projects have been introduced, of which 9 are imported innovative drugs and 13 are imported generic drugs.China's biopharmaceutical research and development spending was 1,541 million yuan, down 5.23 percent from a year earlier and accounting for 12.18 percent of operating income. During the reporting period, the company obtained 12 production approvals, 22 clinical approvals, 9 varieties of evaluation (including the same evaluation); Up to now, the company's cumulative clinical approval, clinical trials and declared production of a total of 438 products in research, including 38 drugs for liver disease, 189 anti-tumor drugs, 22 respiratory drugs, 24 endocrine drugs, 35 cardiovascular drugs and other types of drugs 130.Stone Pharmaceutical Group's research and development expenses amounted to 1,452 million yuan, an increase of 54.24% over the same period last year, accounting for 11.54% of operating income. During the reporting period, the company obtained 9 drug registration approvals, 5 clinical approvals, 12 varieties (18 product regulations) through consistent evaluation, 1 generic drug approved by the FDA for listing, 1 preparation modified new drug application for listing. By the end of the reporting period, the company's research and development team of more than 2000 people, more than 300 research projects, including more than 40 small molecule innovative drugs, more than 50 large molecule innovative drugs, more than 20 new preparations; During the pending phase, 42 products are undergoing clinical trials (31 innovative drugs, 11 new preparations), 9 products are undergoing bioexuality trials, and 7 products are in clinical approval (6 domestic and 1 U.S.).

nearly 80% of pharmaceutical companies increased investment in research and development, these seven increased by more than 100% year-on-The outbreak of new crown pneumonia in 2020 has affected economic growth in all industries, and the pharmaceutical industry is not immune, but most pharmaceutical companies continue to increase investment in research and development. Of the 120 pharmaceutical companies that invested 50 million yuan in research and development in the first half of 2020, 94 showed positive growth in research and development investment compared with the same period last year, accounting for nearly 80%.A total of 7 companies with more than 100% year-on-year investment in research and development, including Dongsian Pharmaceuticals (500.60%), Yongtai Bio-B (306.1%), Xiang Xue Pharmaceuticals (294.06%), and No Chengjian Hua-B (143.88%), Corning Jerry Pharmaceuticals-B (139.86%), Hainan Hai Medicine (120.61%), Wanfu Bio (116.95%).Dongsin Pharmaceuticals invested 685 million yuan in research and development, an increase of 500.6 percent over the same period last year, accounting for 32.86 percent of operating income. During the reporting period, the company's first biological recombinant human insulin injection was approved for sale, three generics were approved for production, and another 10-12 varieties are expected to be approved for listing this year; As of the end of the reporting period, class 1 new drug phosphate emitavir (NS5A inhibitors) was declared on the market and is expected to be approved in the second half of 2020; According to Minenet data, there are currently more than 30 new drugs (excluding API and listed varieties) in Dongsian Pharmaceuticals, of which more than 20 are in the first category of new drugs.Xiang Xue Pharmaceutical invested 193 million yuan in research and development, an increase of 294.06 percent over the same period last year, accounting for 10.65 percent of operating income. The company's main business for modern Chinese medicine and Chinese medicine tablets research and development, production and sales, in recent years gradually involved in the research and development of chemical drugs. As of the end of the reporting period, the company's new class 1 drug KX02 tablets, TAEST16001 injections are in phase I clinical, STP705 is in the process of clinical preparation for phase I.The research and development cost of Noshing Jianhua-B was 231 million yuan, an increase of 143.88 percent over the same period last year. During the reporting period, the first class 1 new drug, Aoptinib (BTK inhibitor), submitted two new drug listing applications (recurring difficulty treating CLL/SLL and MRL). At the end of the reporting period, the company had 287 employees, 173 of whom were research and developers, and among the new class 1 drugs, ICP-192 (pan-FGFR inhibitors) were conducting Phase II clinical, and ICP-105 (FGFR4 inhibitors) were in Phase I clinical, ICP-723 (TRK inhibitors) approved clinical, ICP-332 (TYK2 inhibitors), ICP-189 (SHP2 variant inhibitors), ICP-490, etc. in the IND preparation stage.

42 pharmaceutical companies accounted for 10% or more of revenue, and these five companies accounted for more than 100%Ten of the 120 pharmaceutical companies have not yet commercialized their products, 42 pharmaceutical companies have invested more than 10% of their operating income in research and development, Dongxuan Pharmaceuticals-B (762.28%), Andotai (501. 35%), Baiji Shenzhou (501.27%), Goli Pharmaceuticals-B (162.51%), Junshi Bio (123.30%) 5 pharmaceutical companies exceeded 100%.The company 245 million yuan in research and development expenses, down 30.51 percent from the same period last year, accounting for 501.35 percent of revenue. By the end of the reporting period, the company's research and development team had 249 people, and one product was approved for production (BAT1406), the first Adami mono-biosynthic drug in China, with sales revenue of RMB 449 million in the first half of 2020; Products are under study, 2 have submitted applications for listing (innovative drug BAT2094, biosynthic drug BAT1706), 3 are in phase III clinical stage (BAT1806, BAT2506, BAT8001).Junshi Bio research and development expenditure of 709 million yuan, an increase of 92.00 percent over the same period last year, accounting for 123.30 percent of revenue. During the reporting period, JS001 (Triple Monoanti) is conducting 15 key registered clinical trials (2 have submitted NDA applications), the first new coronavirus-intransific antibody JS016 (recombinant all-human source anti-SARS-CoV-2 monoantigen injection) into Phase I clinical, JS TAB004 (BTLA monoantigen) approved clinical. By the end of the reporting period, the company was working on 21 products (19 innovative drugs and 2 bioso analog drugs) covering malignant tumors, autoimmune diseases, chronic metabolic diseases, neurological diseases and infectious diseases, of which UDP1213 (Adamo monobial-like drugs) has been applied for market. (Minenet)